Form 4 for INBX Inhibrx Biosciences, Inc.
Accepted 2024-05-31 00:00:00 ET · period of report 2024-05-29 · accession 0000950170-24-067359 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-31 | 2024-05-29 | INBX | Inhibrx, Inc. | 10% | J - Other | — | -13.32M | 1.16M | -92% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 per share | 2024-05-29 | J | D | 13,316,140 | — | 1,157,926 | D | — | — | (F1) On January 8, 2024, Inhibrx, Inc. ("RemainCo"), acquired 100 shares, par value $0.0001 per share (the "Common Stock"), of Inhibrx Biosciences, Inc. (the "Issuer"), which at the time constituted all of the issued and outstanding Common Stock of the Issuer. On May 29, 2024, the Common Stock was split, resulting in RemainCo's ownership of an aggregate 14,474,066 shares of Common Stock of the Issuer. (F2) On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024. |